Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer

被引:151
作者
Menon, U
Skates, SJ
Lewis, S
Rosenthal, AN
Rufford, B
Sibley, K
MacDonald, N
Dawnay, A
Jeyarajah, A
Bast, RC
Oram, D
Jacobs, IJ
机构
[1] UCL, Inst Womens Hlth, EGA Hosp, London WC1E 6DH, England
[2] UCL, Inst Womens Hlth, Dept Gynecol Oncol, London WC1E 6DH, England
[3] Massachusetts Gen Hosp, Ctr Biostat, Boston, MA 02114 USA
[4] Harvard Univ, Sch Med, Boston, MA 02115 USA
[5] UCL Hosp, Barts & London NHS Trust, US Dept Gynecol Oncol, Barts & London NHS Trust,London Dept Clin Biochem, London, England
[6] MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA
关键词
POSTMENOPAUSAL WOMEN; PROSTATE; LUNG; MANAGEMENT; ULTRASOUND; CA125;
D O I
10.1200/JCO.2005.01.6642
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose To evaluate prevalence screening in the first prospective trial of a new ovarian cancer screening (OCS) strategy (risk of ovarian cancer or ROC algorithm) on the basis of age and CA125 profile. Patients and Methods Postmenopausal women, >= 50 years were randomly assigned to a control group or screen group. Screening involved serum CA125, interpreted using the ROC algorithm. Participants with normal results returned to annual screening; those with intermediate results had repeat CA125 testing; and those with elevated values underwent transvaginal ultrasound (TVS). Women with abnormal or persistently equivocal TVS were referred for a gynecologic opinion. Results Thirteen thousand five hundred eighty-two women were recruited. Of 6,682 women randomly assigned to screening, 6,532 women underwent the first screen. After the initial CA125, 5,213 women were classified as normal risk, 91 women elevated, and 1,228 women intermediate. On repeat CA125 testing of the latter, a further 53 women were classified as elevated risk. All 144 women with elevated risk had TVS. Sixteen women underwent surgery. Eleven women had benign pathology; one woman had ovarian recurrence of breast cancer; one woman had borderline; and three women had primary invasive epithelial ovarian cancer (EOC). The specificity and positive predictive value (PPV) for primary invasive EOC were 99.8% (95% CI, 99.7 to 99.9) and 19% (95% CI, 4.1 to 45.6), respectively Conclusion An OCS strategy using the ROC algorithm is feasible and can achieve high specificity and PPV in postmenopausal women. It is being used in the United Kingdom Collaborative Trial of Ovarian Cancer Screening and in the United States in both the Cancer Genetics Network and the Gynecology Oncology Group trials of high-risk women.
引用
收藏
页码:7919 / 7926
页数:8
相关论文
共 20 条
[1]   Micropapillary and cribriform patterns in ovarian serous tumors of low malignant potential - A study of 99 advanced stage cases [J].
Deavers, MT ;
Gershenson, DM ;
Tortolero-Luna, G ;
Malpica, A ;
Lu, KH ;
Silva, EG .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2002, 26 (09) :1129-1141
[2]  
EINHORN N, 1992, OBSTET GYNECOL, V80, P14
[3]   The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: History, organization, and status [J].
Gohagan, JK ;
Prorok, PC ;
Hayes, RB ;
Kramer, BS .
CONTROLLED CLINICAL TRIALS, 2000, 21 (06) :251S-272S
[4]  
Hartge, 2000, Ann Epidemiol, V10, P465, DOI 10.1016/S1047-2797(00)00160-5
[5]   Design and evolution of the data management systems in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial [J].
Hasson, MA ;
Fagerstrom, RM ;
Kahane, DC ;
Walsh, JH ;
Myers, MH ;
Caughman, C ;
Wenzel, B ;
Haralson, JC ;
Flickinger, LM ;
Turner, LM .
CONTROLLED CLINICAL TRIALS, 2000, 21 (06) :329S-348S
[6]   Etiologic and early marker studies in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial [J].
Hayes, RB ;
Reding, D ;
Kopp, W ;
Subar, AF ;
Bhat, N ;
Rothman, N ;
Caporaso, N ;
Ziegler, RG ;
Johnson, CC ;
Weissfeld, JL ;
Hoover, RN ;
Hartge, P ;
Palace, C ;
Gohagan, JK .
CONTROLLED CLINICAL TRIALS, 2000, 21 (06) :349S-355S
[7]  
JACOBS I, 1988, LANCET, V1, P268
[8]   PREVALENCE SCREENING FOR OVARIAN-CANCER IN POSTMENOPAUSAL WOMEN BY CA 125 MEASUREMENT AND ULTRASONOGRAPHY [J].
JACOBS, I ;
DAVIES, AP ;
BRIDGES, J ;
STABILE, I ;
FAY, T ;
LOWER, A ;
GRUDZINSKAS, JG ;
ORAM, D .
BRITISH MEDICAL JOURNAL, 1993, 306 (6884) :1030-1034
[9]   Screening for ovarian cancer: a pilot randomised controlled trial [J].
Jacobs, IJ ;
Skates, SJ ;
MacDonald, N ;
Menon, U ;
Rosenthal, AN ;
Davies, AP ;
Woolas, R ;
Jeyarajah, AR ;
Sibley, K ;
Lowe, DG ;
Oram, DH .
LANCET, 1999, 353 (9160) :1207-1210
[10]   Ultrasound assessment of ovarian cancer risk in postmenopausal women with CA125 elevation [J].
Menon, U ;
Talaat, A ;
Jeyarajah, AR ;
Rosenthal, AN ;
MacDonald, ND ;
Skates, SJ ;
Sibley, K ;
Oram, DH ;
Jacobs, IJ .
BRITISH JOURNAL OF CANCER, 1999, 80 (10) :1644-1647